Merck, Bayer's trial win for heart failure rival could actually boost Novartis' Entresto

19th November 2019 Uncategorised 0

Novartis’ Entresto, the clear-cut market leader in heart failure, has been soul-searching since its highly touted trial in an untreated population fell flat. Now, a surprise competitor has cropped up—but Merck and Bayer’s upstart could actually give Novartis a boost.

More: Merck, Bayer's trial win for heart failure rival could actually boost Novartis' Entresto
Source: fierce